Protocol · Lose fat

GLP-1 Reset

Appetite-quieting metabolic reset for meaningful weight loss.

In this protocol

Overview

GLP-1 Reset is a metabolic reset built around quieting appetite and producing meaningful, sustained weight loss. It centers on two peptides that work through complementary hormonal pathways: Semaglutide and Cagrilintide. Semaglutide is a GLP-1 receptor agonist - the same mechanism behind Ozempic and Wegovy, which are FDA-approved. It mimics the GLP-1 hormone your gut releases after eating, slowing gastric emptying, reducing appetite, and improving blood sugar regulation. Cagrilintide adds a second layer. It's a long-acting amylin analog - amylin is another fullness hormone released by the pancreas - that further slows gastric emptying and strengthens the satiety signal after meals. Together, this pairing is the basis of CagriSema, a combination that has shown strong results in clinical trials. The effect isn't just suppression - it's a genuine recalibration of how the body registers hunger and fullness. Both peptides are injected once weekly, on the same day, and titrated up slowly. Starting at low doses and increasing over weeks is important - it's how nausea and GI side effects are minimized. Ongoing supervision is standard for this protocol because titration is individualized. Over the course of the protocol, patients typically experience a meaningful reduction in hunger, smaller appetite overall, and progressive weight loss. The effect is cumulative and dose-dependent. This is a clinical protocol. Semaglutide requires attention to personal and family history of medullary thyroid cancer, and GI side effects are common early on. Cagrilintide is investigational. Exact titration schedules, monitoring, and protocol duration are determined with a licensed provider in the PepDepo network at your consult.

How it runs

Both once weekly on the same day, slowly titrated up.

Semaglutide controls appetite and blood sugar while Cagrilintide adds amylin-driven fullness, the pairing behind CagriSema.

Questions

What makes this different from just taking semaglutide alone?⌄

Cagrilintide adds the amylin pathway - a separate fullness signal - on top of the GLP-1 pathway from semaglutide. The combination targets both mechanisms simultaneously, which is why the CagriSema pairing has shown stronger outcomes in trials than either agent alone.

How is this stack run?⌄

Both Semaglutide and Cagrilintide are injected subcutaneously once per week, on the same day each week. Both are slowly titrated up from low starting doses to reduce the risk of nausea and GI side effects. This is an ongoing protocol under clinician supervision.

Will I feel nauseated?⌄

Nausea and GI upset are the most common side effects of GLP-1 and amylin-based therapy, particularly early on. Slow titration is specifically designed to minimize this. Most people find that GI side effects settle as the dose stabilizes.

Is Cagrilintide FDA-approved?⌄

Semaglutide is FDA-approved (as Ozempic and Wegovy). Cagrilintide is investigational - it does not have FDA approval and is used in the context of supervised clinical protocols. Your licensed provider in the PepDepo network will review this with you at consult.

Is there anyone who cannot use this stack?⌄

Semaglutide is contraindicated for people with a personal or family history of medullary thyroid cancer. Both peptides are excluded for pregnant patients. These are reviewed at your health intake before the protocol begins.

How long does the protocol run?⌄

Both peptides are described as ongoing under supervision. There is no fixed endpoint - the duration is determined by your response, goals, and clinician assessment. This is not a short-cycle intervention.

Does dosing differ for men and women?⌄

Semaglutide is dosed by response, not sex, and titrated slowly for everyone. Your starting dose and target dose are set based on your individual response and tolerance, not a fixed formula.

Run this protocol safely

A licensed provider in the PepDepo network sets your exact protocol and dosing.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.